Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05943626 · ClinicalTrials.gov registry record · NA
Circadian Intervention to Improve Cardiometabolic Health
A NA study of Type 2 Diabetes and Sleep, sponsored by University of Utah.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05943626: Recruiting NA study of Type 2 Diabetes and Sleep, sponsored by University of Utah.
NCT05943626 is a NA study of Type 2 Diabetes and Sleep that is actively recruiting participants, run by University of Utah. The registered enrollment target is 20 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05943626, a NA study of Type 2 Diabetes and Sleep, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a randomized controlled trial, with circadian intervention and control (healthy lifestyle) groups. The circadian intervention is designed to reduce nighttime light exposure and after-dinner snack food intake. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).
Primary Outcome
Oral Glucose Tolerance Test (OGTT), Matsuda Index
Conditions Studied
Interventions
- BEHAVIORAL Circadian Intervention
Study Locations (1)
Utah
- College of Health Research Complex--University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2026-03 |
| Phase | NA |
What NCT05943626 shows while recruiting
NCT05943626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 9 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Circadian Intervention is the first listed.
NCT05943626 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05943626 about?
NCT05943626 is a clinical study titled "Circadian Intervention to Improve Cardiometabolic Health". The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a randomized controlled trial, with circadian intervention and control (healthy lifestyle) groups. The circadian intervent...
What is the current status of trial NCT05943626?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2023-06-13. Estimated completion is 2026-03.
What conditions does trial NCT05943626 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Sleep, Overweight and Obesity, Insulin Sensitivity, Sleep Hygiene.
What interventions are being tested in trial NCT05943626?
The interventions under investigation include: Circadian Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05943626?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05943626 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05943626's enrollment target sits among peer trials
20 290th of 327 higher than 23 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI